These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 17596700

  • 1. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease.
    Wu M, Wahl PR, Le Hir M, Wackerle-Men Y, Wuthrich RP, Serra AL.
    Kidney Blood Press Res; 2007; 30(4):253-9. PubMed ID: 17596700
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
    Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wüthrich RP.
    Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
    [Abstract] [Full Text] [Related]

  • 3. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease.
    Tao Y, Kim J, Schrier RW, Edelstein CL.
    J Am Soc Nephrol; 2005 Jan; 16(1):46-51. PubMed ID: 15563559
    [Abstract] [Full Text] [Related]

  • 4. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease.
    Wu M, Arcaro A, Varga Z, Vogetseder A, Le Hir M, Wüthrich RP, Serra AL.
    Am J Physiol Renal Physiol; 2009 Dec; 297(6):F1597-605. PubMed ID: 19776171
    [Abstract] [Full Text] [Related]

  • 5. Mitotic activation of Akt signalling pathway in Han:SPRD rats with polycystic kidney disease.
    Wahl PR, Le Hir M, Vogetseder A, Arcaro A, Starke A, Waeckerle-Men Y, Serra AL, Wuthrich RP.
    Nephrology (Carlton); 2007 Aug; 12(4):357-63. PubMed ID: 17635750
    [Abstract] [Full Text] [Related]

  • 6. Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease.
    Berthier CC, Wahl PR, Le Hir M, Marti HP, Wagner U, Rehrauer H, Wüthrich RP, Serra AL.
    Nephrol Dial Transplant; 2008 Mar; 23(3):880-9. PubMed ID: 18042615
    [Abstract] [Full Text] [Related]

  • 7. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat.
    Vogelbacher R, Wittmann S, Braun A, Daniel C, Hugo C.
    Transplantation; 2007 Dec 15; 84(11):1492-9. PubMed ID: 18091526
    [Abstract] [Full Text] [Related]

  • 8. Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD).
    Zafar I, Belibi FA, He Z, Edelstein CL.
    Nephrol Dial Transplant; 2009 Aug 15; 24(8):2349-53. PubMed ID: 19321761
    [Abstract] [Full Text] [Related]

  • 9. Mycophenolate mofetil versus Rapamycin in Han: SPRD rats with Polycystic Kidney Disease.
    Zhang T, Wang L, Xiong X, Mao Z, Wang L, Mei C.
    Biol Res; 2009 Aug 15; 42(4):437-44. PubMed ID: 20140299
    [Abstract] [Full Text] [Related]

  • 10. Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats.
    Wang X, Zhang S, Liu Y, Spichtig D, Kapoor S, Koepsell H, Mohebbi N, Segerer S, Serra AL, Rodriguez D, Devuyst O, Mei C, Wüthrich RP.
    Kidney Int; 2013 Nov 15; 84(5):962-8. PubMed ID: 23715121
    [Abstract] [Full Text] [Related]

  • 11. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
    Wüthrich RP, Kistler AD, Serra AL.
    Transplant Proc; 2010 Nov 15; 42(9 Suppl):S44-6. PubMed ID: 21095452
    [Abstract] [Full Text] [Related]

  • 12. An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease.
    Ravichandran K, Zafar I, Ozkok A, Edelstein CL.
    Nephrol Dial Transplant; 2015 Jan 15; 30(1):45-53. PubMed ID: 25239638
    [Abstract] [Full Text] [Related]

  • 13. A new in vitro bioassay for cyst formation by renal cells from an autosomal dominant rat model of polycystic kidney disease.
    Pey R, Bach J, Schieren G, Gretz N, Hafner M.
    In Vitro Cell Dev Biol Anim; 1999 Jan 15; 35(10):571-9. PubMed ID: 10614866
    [Abstract] [Full Text] [Related]

  • 14. Hereditary error in epidermal growth factor prohormone metabolism in a rat model of autosomal dominant polycystic kidney disease.
    Lakshmanan J, Eysselein V.
    Biochem Biophys Res Commun; 1993 Dec 30; 197(3):1083-93. PubMed ID: 8280123
    [Abstract] [Full Text] [Related]

  • 15. Dietary soy protein selectively reduces renal prostanoids and cyclooxygenases in polycystic kidney disease.
    Peng CY, Sankaran D, Ogborn MR, Aukema HM.
    Exp Biol Med (Maywood); 2009 Jul 30; 234(7):737-43. PubMed ID: 19429858
    [Abstract] [Full Text] [Related]

  • 16. Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats.
    Dai B, Liu Y, Mei C, Fu L, Xiong X, Zhang Y, Shen X, Hua Z.
    Clin Sci (Lond); 2010 Jul 09; 119(8):323-33. PubMed ID: 20507283
    [Abstract] [Full Text] [Related]

  • 17. Contribution of renal innervation to hypertension in rat autosomal dominant polycystic kidney disease.
    Gattone VH, Siqueira TM, Powell CR, Trambaugh CM, Lingeman JE, Shalhav AL.
    Exp Biol Med (Maywood); 2008 Aug 09; 233(8):952-7. PubMed ID: 18480417
    [Abstract] [Full Text] [Related]

  • 18. Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease.
    Edelstein CL.
    Clin J Am Soc Nephrol; 2008 Jul 09; 3(4):1219-26. PubMed ID: 18587045
    [Abstract] [Full Text] [Related]

  • 19. mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats.
    Nakagawa S, Masuda S, Nishihara K, Inui K.
    Biochem Pharmacol; 2010 Jan 01; 79(1):67-76. PubMed ID: 19660439
    [Abstract] [Full Text] [Related]

  • 20. Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease.
    Tao Y, Kim J, Faubel S, Wu JC, Falk SA, Schrier RW, Edelstein CL.
    Proc Natl Acad Sci U S A; 2005 May 10; 102(19):6954-9. PubMed ID: 15863619
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.